NOVA:FRA
Novo Nordisk A/S
€36.90
arrow_upward
+1.60%(+0.58) 1D
ඉල් 13, 22.00.00 ග්‍රිමවේ+1 · EUR
search
සියලු සංකේත
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_autoNOVA සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
විවෘත කරන්න
€36.42
ඉහළ
€37.34
පහළ
€36.42
වෙ.පො ප්‍රාග්ධනය
බි142.04
දළ පරිමාව
655.00
හඬ පරිමාණය
490.00
සති-52 ඉහළ
€54.80
සති-52 පහළ
€30.45
සේවකයින් ගණන
ද67
විවෘත කරන්න
€36.42
ඉහළ
€37.34
පහළ
€36.42
වෙ.පො ප්‍රාග්ධනය
බි142.04
දළ පරිමාව
655.00
හඬ පරිමාණය
490.00
සති-52 ඉහළ
€54.80
සති-52 පහළ
€30.45
සේවකයින් ගණන
ද67
පුවත් සහ කථා
වෙබ් මූලාශ්‍ර සහ ප්‍රවෘත්ති හවුල්කරුවන්ගෙන්
The Motley Fool
·
පැය 13කට පෙර
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Traders Union
·
දින 1කට පෙර
Novo Nordisk stock rises over 2% as company pledges $200 million to World Diabetes Foundation and lifts guidance
Investing.com
·
දින 2කට පෙර
Novo Nordisk partners with DJ Khaled for Wegovy campaign
The Motley Fool
·
දින 3කට පෙර
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
පැතිකඩ
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Novo Nordisk A/S ගැන
CEOMike Doustdar
සේවකයින්ද66.7
ආරම්භ කළේ1923
මූලස්ථානයBagsværd, ඩෙන්මාර්ක් අග නගරය, ඩෙන්මාර්කය
අංශයHealth Care
කර්මාන්තය-
වෙබ් අඩවියnovonordisk.com